Advances in the management of lung & gastro-intestinal cancers: clinical studies review from ASCO 2022/2023 annual meetings.

IF 2.4 Q3 Medicine
Hafsa Elmarrachi, Meriem Andrif, Nabil Ismaili
{"title":"Advances in the management of lung & gastro-intestinal cancers: clinical studies review from ASCO 2022/2023 annual meetings.","authors":"Hafsa Elmarrachi, Meriem Andrif, Nabil Ismaili","doi":"10.1016/j.ctarc.2025.100974","DOIUrl":null,"url":null,"abstract":"<p><p>Advancements in cancer research play a pivotal role in enhancing prevention, diagnosis, and treatment strategies. The American Society of Clinical Oncology (ASCO) convenes major annual meetings, gathering experts worldwide to discuss the latest discoveries and trends in the field. In this study, we conducted a comprehensive bibliographic analysis of ASCO presentations and publications from 2022 to 2023 to identify dominant themes in cancer research. Our research methodology involved targeted searches in bibliographic databases and ASCO meeting archives, utilizing specific keywords related to various cancer types. Subsequently, we rigorously selected studies based on predefined criteria, with a particular focus on lung and gastrointestinal cancers due to their prevalence and significant public health impact. Among notable studies, evaluations of immune checkpoint inhibitors in advanced gastrointestinal cancers revealed promising response rates, while precision medicine approaches showed significant improvements in clinical outcomes. Studies like PARADIGM and PRODIGE demonstrated the efficacy of novel therapeutic combinations, while the NEO-PAN trial explored new avenues in locally advanced pancreatic cancer treatment. Additionally, novel therapeutic options such as Mobocertinib and sotorasib were identified as offering new hope for patients with specific lung cancers. Studies KEYNOTE-799 and SKYSCRAPER also demonstrated significant survival improvements in patients with stomach, esophageal, and non-small cell lung cancers. Furthermore, the PROTECT study underscored the crucial importance of efforts to reduce severe chemotherapy-related side effects, potentially enhancing patients' quality of life. These findings highlight the significance of ASCO meetings as a vital source of information and collaboration in the fight against cancer, providing valuable insights for the clinical management of this complex disease.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"100974"},"PeriodicalIF":2.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ctarc.2025.100974","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Advancements in cancer research play a pivotal role in enhancing prevention, diagnosis, and treatment strategies. The American Society of Clinical Oncology (ASCO) convenes major annual meetings, gathering experts worldwide to discuss the latest discoveries and trends in the field. In this study, we conducted a comprehensive bibliographic analysis of ASCO presentations and publications from 2022 to 2023 to identify dominant themes in cancer research. Our research methodology involved targeted searches in bibliographic databases and ASCO meeting archives, utilizing specific keywords related to various cancer types. Subsequently, we rigorously selected studies based on predefined criteria, with a particular focus on lung and gastrointestinal cancers due to their prevalence and significant public health impact. Among notable studies, evaluations of immune checkpoint inhibitors in advanced gastrointestinal cancers revealed promising response rates, while precision medicine approaches showed significant improvements in clinical outcomes. Studies like PARADIGM and PRODIGE demonstrated the efficacy of novel therapeutic combinations, while the NEO-PAN trial explored new avenues in locally advanced pancreatic cancer treatment. Additionally, novel therapeutic options such as Mobocertinib and sotorasib were identified as offering new hope for patients with specific lung cancers. Studies KEYNOTE-799 and SKYSCRAPER also demonstrated significant survival improvements in patients with stomach, esophageal, and non-small cell lung cancers. Furthermore, the PROTECT study underscored the crucial importance of efforts to reduce severe chemotherapy-related side effects, potentially enhancing patients' quality of life. These findings highlight the significance of ASCO meetings as a vital source of information and collaboration in the fight against cancer, providing valuable insights for the clinical management of this complex disease.

肺癌和胃肠道癌症治疗的进展:ASCO 2022/2023年年会的临床研究综述
癌症研究的进步在加强预防、诊断和治疗策略方面发挥着关键作用。美国临床肿瘤学会(ASCO)每年召开重大会议,聚集世界各地的专家讨论该领域的最新发现和趋势。在这项研究中,我们对2022年至2023年ASCO的演讲和出版物进行了全面的书目分析,以确定癌症研究的主要主题。我们的研究方法包括在书目数据库和ASCO会议档案中进行有针对性的搜索,利用与各种癌症类型相关的特定关键词。随后,我们根据预先确定的标准严格选择研究,特别关注肺癌和胃肠道癌症,因为它们的患病率和对公共卫生的重大影响。在值得注意的研究中,免疫检查点抑制剂在晚期胃肠道癌症中的评估显示出有希望的反应率,而精准医学方法在临床结果方面显示出显着改善。PARADIGM和PRODIGE等研究证明了新型治疗组合的疗效,而NEO-PAN试验探索了局部晚期胰腺癌治疗的新途径。此外,新的治疗选择,如Mobocertinib和sotorasib被确定为特定肺癌患者提供了新的希望。KEYNOTE-799和SKYSCRAPER的研究也显示了胃癌、食管癌和非小细胞肺癌患者的显著生存改善。此外,PROTECT研究强调了努力减少与化疗相关的严重副作用的重要性,这可能会提高患者的生活质量。这些发现突出了ASCO会议作为抗癌信息和合作的重要来源的重要性,为这种复杂疾病的临床管理提供了有价值的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
148
审稿时长
56 days
期刊介绍: Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信